Trial Profile
A Single-Center, Phase II Trial of Sunitinib and Capecitabine in First Line Treatment of Patients With Metastatic Colorectal Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Apr 2018
Price :
$35
*
At a glance
- Drugs Sunitinib (Primary) ; Capecitabine
- Indications Colorectal cancer
- Focus Therapeutic Use
- 23 Mar 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 20 Aug 2009 New trial record